NCT03099239View on ClinicalTrials.gov

hCT-MSCs for Children With Autism Spectrum Disorder (ASD)

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 6, 2017

Primary Completion Date

June 10, 2019

Study Completion Date

June 10, 2019

Conditions
AutismAutism Spectrum DisorderASD
Interventions
BIOLOGICAL

hCT-MSC infusion

hCT-MSCs are a product of allogeneic cells manufactured from digested umbilical cord tissue that is expanded in culture, cryopreserved and banked.

Trial Locations (1)

27705

Duke University Medical Center, Durham

All Listed Sponsors
collaborator

The Marcus Foundation

OTHER

lead

Joanne Kurtzberg, MD

OTHER

NCT03099239 - hCT-MSCs for Children With Autism Spectrum Disorder (ASD) | Biotech Hunter | Biotech Hunter